Multiple System Atrophy market is projected to boost by the expected launch of pipeline therapies by key players during the forecast period (2021-30)

Multiple System Atrophy Market

DelveInsight’s Multiple System Atrophy market report provides an in-depth understanding of the Multiple System Atrophy, historical and forecasted epidemiology, as well as Multiple System Atrophy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report also discusses current Multiple System Atrophy treatment practises, market drivers, market barriers, unmet medical needs, a SWOT analysis to select the best opportunities, and an assessment of the market’s underlying potential.

Some of the Important Finding from the Multiple System Atrophy Market Report

• As per DelveInsight Multiple System Atrophy epidemiology insights, the total prevalent population was estimated to be 43,023  in 7MM in 2020.

• In the United States, the Multiple System Atrophy prevalent population was more than 15,000 in 2020. 

• Males are more likely to develop Multiple System Atrophy than females. Males accounted for 60% of all Multiple System Atrophy prevalent cases in the United States in 2020.

• Verdiperstat (AZD3241; BHV-3241) (Biohaven Pharmaceuticals), Ampreloxetine (TD-9855) (Theravance Biopharma), Safinamide Methanesulfonate (Zambon SpA), NBMI (Irminix, Emeramide) (EmeraMed), and others are among the Multiple System Atrophy emerging therapies.

• Key players, such as Biohaven Pharmaceuticals, Theravance Biopharma, Zambon SpA, EmeraMed, AFFiRiS AG, and others are developing therapies for Multiple System Atrophy treatment.

Request sample to know more about MSA @ Multiple System Atrophy Market Forecast

The Multiple System Atrophy market report covers current treatment practises, emerging drugs, and market share of individual therapies, as well as the current and projected 7MM Multiple System Atrophy market size from 2018 to 2030.

Multiple System Atrophy: Overview

Multiple System Atrophy is a progressive neurodegenerative condition marked by a combination of symptoms affecting the autonomic nervous system (the component of the nervous system that regulates involuntary functions like blood pressure and digestion) as well as movement. The symptoms are caused by the progressive death and loss of function of many types of nerve cells in the brain and spinal cord.

Multiple System Atrophy Epidemiology Segmentation

• Multiple System Atrophy Total Prevalent Cases 

• Multiple System Atrophy Total Diagnosed Prevalent Cases

• Multiple System Atrophy Gender-Specific Diagnosed Prevalent Cases

• Multiple System Atrophy Age-Specific Diagnosed Prevalent Cases 

• Multiple System Atrophy Type-Specific Diagnosed Prevalent Cases

Multiple System Atrophy Treatment Landscape

Multiple System Atrophy does not have a specific treatment. Supportive therapies (physiotherapy, occupational therapy, and speech therapy) as well as treatment of autonomic symptoms are used to control the Multiple System Atrophy symptoms. Drugs used to treat Parkinson’s disease, particularly levodopa, may also be prescribed for people with Multiple System Atrophy.

Multiple System Atrophy Market

Increased patient pool and anticipated entry of emerging therapies such as Verdiperstat (AZD3241; BHV-3241) (Biohaven Pharmaceuticals), Ampreloxetine (TD-9855) (Theravance Biopharma), Safinamide Methanesulfonate (Zambon SpA), NBMI (Irminix, Emeramide) (EmeraMed), will drive the Multiple System Atrophy market during the forecasted period (2021–2030).

Get a detailed analysis on multiple system atrophy @ Multiple System Atrophy Market Analysis

Multiple System Atrophy Pipeline Therapies and Key Companies 

• Verdipersta (AZD3241; BHV-3241): Biohaven Pharmaceuticals

• Ampreloxetine (TD-9855: Theravance Biopharma

• Safinamide Methanesulfonate: Zambon SpA

• NBMI ( Irminix, Emeramide): EmeraMed

Multiple System Atrophy Market Drivers

• Major recent advancements in disease understanding

• New preclinical model

• Pipeline Advancement

Multiple System Atrophy Market Barriers

• Lack of disease understanding

• A limited number of participants

• The sudden death of the patients in sleep

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2018-30

Multiple System Atrophy Key Companies: Biohaven Pharmaceuticals, Theravance Biopharma, Zambon SpA, EmeraMed, AFFiRiS AG, among others. 

Multiple System Atrophy Key Pipeline Therapies: Verdiperstat (AZD3241; BHV-3241) (Biohaven Pharmaceuticals), Ampreloxetine (TD-9855) (Theravance Biopharma), Safinamide Methanesulfonate (Zambon SpA), NBMI (Irminix, Emeramide) (EmeraMed), and others.

Multiple System Atrophy Segmentation: By Geography, Multiple System Atrophy drugs

Analysis: Comparative and conjoint analysis of  Multiple System Atrophy emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Multiple Myeloma Market

Get comprehensive historical and forecast analysis of Multiple Myeloma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Johnson & Johnson, Roche, Amgen, AstraZeneca, BioLineRx, ExCellThera, Takeda, Bristol-Myers Squibb, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/